the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of Oocyte on Poor Ovarian Response(POR)

Overview

Patients in experimental group will be given transcutaneous electrical acupoint stimulation (TEAS) treatment for 12 weeks prior to controlled ovarian stimulation (COS).The patients will be given three times acupuncture every week except menstruation.Patients in no intervention group will not be given any interventions for 12 weeks prior to COS. The primary outcome measure is the number of MII eggs obtained in the COS cycle. The secondary outcome measures are the lab and clinical reproductive outcomes.

Full Title of Study: “The Clinical Trial of the Effect of Transcutaneous Electrical Acupoint Stimulation on the Quality of the Oocyte on Poor Ovarian Response”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: May 1, 2021

Detailed Description

The patients will be randomly recruited into two groups. Patients in experimental group will be given TEAS treatment for 12 weeks prior to COS.The patients will be given three times acupuncture every week except menstruation. One treatment lasts for 30 minutes. The acupoints used for the TEAS treatment included head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26). Patients in no intervention group will not be given any intervention for 12 weeks prior to COS. When at least one dominant follicle is greater than 18 mm then injection a GnRH agonist (Triptorelin, Ferring, Switzerland) 0.2mg. 36 hours later transvaginal oocyte retrieval will be taken. After 3 hours of incubation, each egg will be transferred with a density of about 100,000/mllive sperm. The fresh embryo transfer is performed 72 hours after embryo culture in vitro. The whole embryos will be frozen. The primary outcome measure is the number of MII eggs obtained in the COS cycle. The secondary outcome measures are the lab and clinical reproductive outcomes,including basic endocrine, serum Anti-Mullerian Hormone (AMH), antral follicle counts, fertilization rate, cleavage rate, number of D3 embryos, the clinical pregnancy rate and early abortion rate.

Interventions

  • Other: TEAS
    • Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).

Arms, Groups and Cohorts

  • Experimental: the TEAS intervention group
    • Patients in this group will be given TEAS treatment for 12 weeks prior to COS.
  • No Intervention: No intervention group
    • Patients in this group will not be given any interventions for 12 weeks prior to COS.

Clinical Trial Outcome Measures

Primary Measures

  • The number of MII eggs
    • Time Frame: one day after oocyte pickup
    • The number of MII eggs obtained in the COS cycle

Secondary Measures

  • Basic Follicle stimulating hormone (FSH) value
    • Time Frame: On Day two of menstruation
    • Basic FSH value in mIU/ml
  • Basic Luteinizing hormone (LH) value
    • Time Frame: On Day two of menstruation
    • Basic LH in mIU/ml
  • Basic estrodiol value
    • Time Frame: On Day two of menstruation
    • Basic estrodiol in pg/ml
  • Serum AMH value
    • Time Frame: On Day two of menstruation
    • Serum AMH in ng/ml
  • antral follicle count
    • Time Frame: antral follicle count On Day two of menstruation
    • antral follicle count
  • fertilization rate
    • Time Frame: fertilization rate calculated on 1 day after oocyte pickup
    • fertilization rate
  • cleavage rate
    • Time Frame: cleavage rate calculated on 2 days after oocyte pickup
    • cleavage rate
  • the number of Day 3 embryos
    • Time Frame: the number of Day 3 embryos calculated on 3 days after oocyte pickup
    • the number of Day 3 embryos
  • clinical pregnancy rate
    • Time Frame: clinical pregnancy rate calculated on the 6th gestational week
    • clinical pregnancy rate
  • early abortion rate
    • Time Frame: early abortion rate calculated on 12th week of pregnancy
    • early abortion rate

Participating in This Clinical Trial

Inclusion Criteria

1. The poor ovarian response patients compliance with Bologna consensus 2. Age:20-45 year 3. Women undergoing IVF-ET because of infertility for more than one year. Exclusion Criteria:

1. Patients with genital tract malformation. Uterine malformation (single uterus, double uterus, double uterus, untreated mediastinal uterus) and other effects affecting uterine cavity disease (adenomyosis, submucosal uterine fibroids, intrauterine adhesions and scar uterus) 2. Complicated with other medical diseases(Hypertension, diabetes, psychosis, hereditary diseases)

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ShangHai Ji Ai Genetics & IVF Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Wenbi Zhang, doctor, Principal Investigator, Fudan University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.